Skip to content
Categories
Satellite Symposium
Satellite Symposium
Satellite Symposium

Chemotherapy-free first line treatment in common EGFR mutated NSCLC - Improving patient outcomes and simplify patient management

- , Shanghai 1-2

Schedule Slot

Chemotherapy-free first line treatment in common EGFR mutated NSCLC - Improving patient outcomes and simplify patient management

Categories
Satellite Symposium
Satellite Symposium
Satellite Symposium

Chemotherapy-free first line treatment in common EGFR mutated NSCLC - Improving patient outcomes and simplify patient management

- , Shanghai 1-2

Endorsed by: Johnson&Johnson